BRAF and non-small cell lung carcinoma: Thus, in the case of BRAF V600-mutant NSCLC, combination therapies involving BRAF and MEK inhibitors such as dabrafenib + trametinib or encorafenib + binimetinib (currently standard of care for the management of these tumors) are effective clinical options (Table 1) [83,84].